Krilogy Financial LLC Acquires 2,487 Shares of Pfizer Inc. (NYSE:PFE)

Krilogy Financial LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 27,678 shares of the biopharmaceutical company’s stock after purchasing an additional 2,487 shares during the period. Krilogy Financial LLC’s holdings in Pfizer were worth $774,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Olistico Wealth LLC bought a new stake in Pfizer in the 2nd quarter worth $25,000. Creekmur Asset Management LLC purchased a new position in Pfizer during the 4th quarter valued at about $32,000. Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in Pfizer in the fourth quarter worth about $37,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.13 during mid-day trading on Wednesday, hitting $29.03. The company had a trading volume of 15,158,918 shares, compared to its average volume of 39,222,289. The company has a market capitalization of $164.50 billion, a P/E ratio of -483.67, a P/E/G ratio of 1.00 and a beta of 0.69. The stock’s 50 day moving average price is $28.78 and its 200-day moving average price is $27.93. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.15.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.79%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.